Particle characterization specialist Gateway Analytical is offering two upcoming webinars of interest to OINDP developers, manufacturers, and quality assurance personnel. The first of the webinars, Ensure Quality Inhalation Products with Wear Debris Analysis of Medical Devices, will take place on May 30. The one-hour webinar will cover causes of wear debris in … [Read more...] about Gateway Analytical offering two webinars for OINDP specialists
News
Pearl Therapeutics wins technology award
Pearl Therapeutics has won a 2012 TiE50 award from the Indus Entrepreneurs (TiE). Pearl was one of ten winners in the life sciences category. Pearl develops inhaled therapies based on its proprietary particle engineering technology. Pearl CEO Chuck Bramlage said, “The TiE organization awards start-ups that put a premium on entrepreneurial spirit, technological … [Read more...] about Pearl Therapeutics wins technology award
Aegis gets second patent for intranasal parathyroid hormone formulations
The US Patent and Trade Office has awarded a second patent, to Aegis Therapeutics for stabilized formulations of parathyroid hormone and parathyroid hormone analogs. The new patent (US Patent No. 8,173,594) covers formulations for both injection and nasal delivery that use Aegis's Intravail and ProTek excipients. Both patents have been licensed to Azelon … [Read more...] about Aegis gets second patent for intranasal parathyroid hormone formulations
US plan to fight Alzheimer’s includes funding for development of insulin nasal spray
US Health and Human Services Secretary Kathleen Sebelius has announced a national plan to fight Alzheimer’s disease that includes almost $8 million in funding for research related to an insulin nasal spray for the treatment of the disease. An article published in the Archives of Neurology in September 2011 described positive results from the SNIFF (Study of Nasal … [Read more...] about US plan to fight Alzheimer’s includes funding for development of insulin nasal spray
Rigel advances development of its inhaled SYK inhibitor and inhaled IL13 signaling/JAK inhibitor
Rigel Pharmaceuticals says that it plans to focus its efforts on two inhaled asthma therapies: R343, an inhaled SYK inhibitor and R256, an inhaled IL13 signaling/JAK inhibitor. A Phase 2 clinical study of R343 will begin later this summer in mild to moderate asthma patients. Rigel said that it plans to initiate a preclinical development program for R256 but did not … [Read more...] about Rigel advances development of its inhaled SYK inhibitor and inhaled IL13 signaling/JAK inhibitor
Positive Phase 2b results for Elevation’s glycopyrrolate inhalation solution
Elevation Pharmaceuticals has announced that a Phase 2b study of its EP-101 glycopyrrolate inhalation solution in patients with moderate to severe COPD demonstrated that EP-101 produced statistically significant improvement in lung function compared to placebo after 7 days. The GOLDEN-1 (Glycopyrrolate for Obstructive Lung Disease via Electronic Nebulizer) study … [Read more...] about Positive Phase 2b results for Elevation’s glycopyrrolate inhalation solution
Insmed appoints Donald J. Hayden, Jr. as Executive Chairman of the Board of Directors
Insmed Incorporated, which is developing Arikace liposomal amikacin for inhalation, has appointed Donald J. Hayden, Jr. as Executive Chairman of its Board of Directors, effective immediately. He has been serving as Chairman of the board of directors since the end of 2010 when Insmed merged with Transave, and he will continue to focus on the development of Arikace … [Read more...] about Insmed appoints Donald J. Hayden, Jr. as Executive Chairman of the Board of Directors
CDC survey shows that almost 19 million US adults have asthma
Data from the Centers for Disease Control and Prevention (CDC) Asthma Call-back Survey show that 18.7 million US adults (8.2 percent) have asthma today out of approximately 29.1 million adults (12.7 percent) who have been diagnosed with asthma at some point in their lifetimes. The data are contained in a report called Asthma’s Impact on the Nation. According to the … [Read more...] about CDC survey shows that almost 19 million US adults have asthma
Pulmatrix touts iSPERSE potential for inhaled therapies
Pulmatrix is presenting two posters at RDD, one titled “Formulation Characterization of a Novel Levofloxacin Pulmonary Dry Powder Drug Delivery Technology,” and the other titled “Development of an iSPERSE Based Platform for the Delivery of Macromolecules via Dry Powder Formulations.” The posters include data from in vitro and preclinical studies of formulations … [Read more...] about Pulmatrix touts iSPERSE potential for inhaled therapies
Study confirms ergonomic advantages of Aptar inhaler
Aptar Pharma is presenting results from a clinical study of patient ability to use its Prohaler DPI at RDD this week. The study, which was conducted by Professor Patrice Diot at the Centre Hospitalier Regional Universitaire (CHRU) in Tours, France, demonstrated that all of the asthma and COPD patients involved in the study, no matter how ill, were able to trigger the … [Read more...] about Study confirms ergonomic advantages of Aptar inhaler